India's Gennova Developing Omicron-Specific COVID-19 Vaccine

[email protected]14 Feb, 2022News

India's Gennova Biopharmaceuticals is working on an Omicron-specific mRNA COVID-19 vaccine candidate, it told Reuters on Monday, after a person with direct knowledge of the matter said the product could be ready in a month or two. "The Omicron-specific variant of the vaccine is under development and will be ready for human clinical trials, subject to regulatory approvals," a company spokesperson said in a text message. "We will keep you posted." The source, who did not want to be named as the information was private, said the product might need a small trial in India before it could be rolled out.